🔍

ANG Lifesciences India Ltd (540694)

📊 BSE: 540694 🏢 Pharmaceuticals 📢 Latest filing: 14 Aug 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, ANG Lifesciences' revenue was ₹15.3 Cr (-37.8% year on year, -34.9% on the previous quarter), and net profit ₹-4.2 Cr (a bigger loss than a year earlier); the operating margin was -12.8%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹15.3	-37.8%	-34.9%
Operating profit	₹-2.0	to loss	to loss
Net profit	₹-4.2	loss widened	loss widened
EPS (₹)	-3.24	loss widened	loss widened
Operating margin	-12.8%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Q1 Cons Loss Widens to ₹4.24 Cr; Revenue Declines 37.8% YoY to ₹15.30 Cr

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 14 Aug 2026, 06:30 PM

ANG Lifesciences reported a 37.8% YoY drop in consolidated revenue from operations to ₹15.30 Cr for the quarter ended June 30, 2026, compared to ₹24.60 Cr in the corresponding prior-year period. Consolidated net loss widened significantly to ₹4.24 Cr against a net loss of ₹2.01 Cr in Q1 FY26. On a standalone basis, revenue dropped 43.1% YoY to ₹13.96 Cr with a net loss of ₹3.42 Cr. High finance costs of ₹2.24 Cr continue to severely strain operational performance against an existing debt load of ₹79 Cr.

Consolidated revenue from operations dropped 37.8% YoY to ₹1,529.77 lakhs (₹15.30 Cr)
Consolidated net loss widened to ₹424.42 lakhs (₹4.24 Cr) vs ₹200.62 lakhs loss in Q1 FY26
Standalone revenue fell to ₹1,395.79 lakhs with a net loss of ₹341.76 lakhs
Finance costs remained high at ₹223.51 lakhs for the quarter on a consolidated basis
Consolidated basic and diluted EPS declined to ₹(3.24) from ₹(1.52) YoY

💡 Track whether revenue can recover to historical run-rates in upcoming quarters and monitor any management commentary regarding debt servicing and cost rationalization.

ANG Lifesciences Q1 Revenue Down 38% YoY to ₹15.3 Cr; Net Loss Widens to ₹4.24 Cr

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 14 Aug 2026, 06:25 PM

ANG Lifesciences reported consolidated revenue from operations of ₹15.30 crore for the quarter ended June 30, 2026, marking a 37.8% YoY decline from ₹24.60 crore in Q1 of the previous year. Consolidated net loss worsened substantially to ₹4.24 crore compared to a loss of ₹2.01 crore in Q1 FY26 and ₹1.38 crore in Q4 FY26. Standalone revenue fell 43.1% YoY to ₹13.96 crore with a standalone net loss of ₹3.42 crore. Persistent high finance costs of ₹2.24 crore continue to hurt operational margins amid a shrinking revenue base.

Consolidated revenue from operations dropped 37.8% YoY to ₹1,529.77 lakhs (₹15.30 cr)
Consolidated net loss widened to ₹424.42 lakhs (₹4.24 cr) vs ₹200.62 lakhs in the year-ago period
Standalone revenue decreased to ₹1,395.79 lakhs with net loss at ₹341.76 lakhs
Consolidated finance costs remained high at ₹223.51 lakhs (₹2.24 cr) for the quarter

💡 Track whether management can arrest the top-line contraction in subsequent quarters and manage cash flows to service debt obligations (D/E of ~1.49).

Board Meeting Scheduled for Aug 14, 2026, to Approve Q1 FY27 Financial Results

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 07 Aug 2026, 12:39 PM

ANG Lifesciences India Ltd has scheduled a board meeting on August 14, 2026, to consider and approve its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. The company is currently in a challenging financial position, reporting a TTM net loss of Rs 11 Cr and carrying a high debt of Rs 79 Cr. Investors will be monitoring if the company can build on the marginal operating profit of Rs 2.68 Cr reported in the March 2026 quarter. The trading window for insiders remains closed until 48 hours after the results are made public.